Press Releases

Pharmacological block of the FATP2 protein selectively inhibits myeloid-derived suppressor cells and shows antitumor effects in preclinical models.

The DNA-encoded monoclonal antibody platform provides rapid and sustained protection against Zika virus infection.

First-in-class pharmacological inhibitors of the EBNA1 viral protein are effective at inhibiting tumor growth in preclinical models.

Philadelphia and San Jose, Calif. – (Feb. 21, 2019) – The Wistar Institute has extended its collaboration with Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer. The project is focused on understanding the role of myeloid-derived suppressor cells (MDSCs) and how they can be used in diagnostic and therapeutic applications—work advanced by Dmitry I.

Increased NAD+ metabolism promotes cancer progression in a preclinical model of pancreatic cancer through increased secretion of senescence-associated proinflammatory molecules.